Colorado Files Lawsuit Against Alvogen Over Opioids

The state alleges the company failed to monitor oxycodone sales, potentially impacting public health recovery funds.

Updated on Oct. 16, 2026 in Substance Abuse

Bold flat-color editorial illustration of a mountain silhouette and its reflection, symbolizing institutional oversight and serious state policy. — Colorado Attorney General Phil Weiser filed a lawsuit against Alvogen, alleging the manufacturer failed to adequately monitor suspicious oxycodone distribution orders. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies be held financially accountable for the national opioid addiction crisis?

The Colorado Attorney General has filed a lawsuit against Alvogen, Inc., alleging the company sold large quantities of generic oxycodone without an effective suspicious order monitoring system. This legal action comes as the state continues to address the impact of the opioid crisis on public health.

Why it matters

This lawsuit seeks to hold manufacturers accountable for distribution practices that may have contributed to opioid accessibility in Colorado. These funds are increasingly critical for supporting recovery infrastructure as the state navigates potential federal spending rollbacks for health programs.

The state's complaint cites distribution data from 2012 onward, highlighting the scale of generic oxycodone sales in the region. While the litigation proceeds, the exact impact of these distribution methods on local overdose rates remains under legal review.

The players

Colorado Attorney General

The chief legal officer of Colorado who represents the state in consumer protection and public health litigation.

Alvogen, Inc.

A pharmaceutical company that produces various medications, including generic oxycodone.

The details

Suspicious order monitoring systems are designed to flag unusual purchase frequencies and quantities that exceed documented medical need. The lawsuit alleges that Alvogen failed to maintain these oversight mechanisms during its generic oxycodone sales period, which began in 2012. These systems act as a critical checkpoint to prevent excessive opioids from entering the pharmaceutical supply chain.

2012: Alvogen began selling generic oxycodone.
2023: 105,000 people died from drug overdoses nationwide.
October 15, 2026: The Colorado Attorney General filed the lawsuit.

Health Landscape

This litigation builds on the nearly $912 million in settlement funds Colorado has secured from opioid-related cases since 2019. It reflects a broader shift toward using legal channels to finance long-term addiction recovery and treatment infrastructure.

This development highlights the ongoing importance of discussing safe pain management and medication monitoring with a physician. Patients concerned about the use of opioids for chronic pain management should speak with their doctor about evidence-based treatment alternatives.

The takeaway

The lawsuit underscores the state's ongoing commitment to funding opioid recovery services through litigation. Residents interested in public health resources or local recovery support programs should consult the Colorado Department of Public Health and Environment for current community services.